Please wait while the formulary information is being retrieved.
ORILISSA (elagolix sodium)
- Endometriosis
150 mg tablet
- 1 tablet (150 mg) by oral route once daily at approximately the same time each day
200 mg tablet
- 1 tablet (200 mg) by oral route 2 times per day at approximatelythe same times each day
Endometriosis
- 1 tablet (150 mg) by oral route once daily at approximately the same time each day
- 1 tablet (150 mg) by oral route once daily at approximately the same time each day for up to 24 months
- 1 tablet (200 mg) by oral route 2 times per day at approximatelythe same times each day
- 1 tablet (200 mg) by oral route 2 times per day at approximatelythe same times each day for up to 6 months
- None
Contraindicated
- axitinib
- bedaquiline
- Bosulif
- bosutinib
- enzalutamide
- guanfacine
- Inlyta
- Intuniv Er
- Olysio
- simeprevir
- Sirturo
- Tenex
- Xtandi
Severe
Moderate
- None
- Osteoporosis
- Pregnancy
- Severe hepatic disease
Contraindicated
- Osteopenia
- Suicidal ideation
Severe
Moderate
- Hypercholesterolemia
- Hypertriglyceridemia
ORILISSA (elagolix sodium)
- Endometriosis
- None
- Amenorrhea
- Arthralgias
- Depression
- Drug-induced hot flash
- Headache disorder
- Insomnia
- Menstrual disorder
- Mood changes
- Nausea
- Night sweats
- Symptoms of anxiety
More Frequent
Severe
Less Severe
- Osteopenia
- Constipation
- Diarrhea
- Dizziness
- Hypercholesterolemia
- Hypertriglyceridemia
- Irritability
- Libido changes
- Skin rash
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Appendicitis
- Suicidal
- Suicidal ideation
Less Severe
- Acute abdominal pain
- Back pain
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Elagolix
No pediatric safety and efficacy.
- 1 Day – 18 Years
- No pediatric safety and efficacy.
Elagolix
- Severity Level:
1
- Additional Notes: Avoid use in pregnancy; possible increased risk for early fetal loss.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Elagolix
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Endometriosis | |
| N80 | Endometriosis |
| N80.0 | Endometriosis of uterus |
| N80.1 | Endometriosis of ovary |
| N80.2 | Endometriosis of fallopian tube |
| N80.3 | Endometriosis of pelvic peritoneum |
| N80.4 | Endometriosis of rectovaginal septum and vagina |
| N80.5 | Endometriosis of intestine |
| N80.6 | Endometriosis in cutaneous scar |
| N80.8 | Other endometriosis |
| N80.9 | Endometriosis, unspecified |
| 0-9 | A-Z |
|---|---|
| N80 | Endometriosis |
| N80.0 | Endometriosis of uterus |
| N80.1 | Endometriosis of ovary |
| N80.2 | Endometriosis of fallopian tube |
| N80.3 | Endometriosis of pelvic peritoneum |
| N80.4 | Endometriosis of rectovaginal septum and vagina |
| N80.5 | Endometriosis of intestine |
| N80.6 | Endometriosis in cutaneous scar |
| N80.8 | Other endometriosis |
| N80.9 | Endometriosis, unspecified |
Formulary Reference Tool